ストックスクリーナーアプリを入手
40.29
1.44%
0.57
プレマーケット:
40.03
-0.26
-0.65%
前日終値:
$39.72
開ける：
$39.76
24時間の取引高:
551.39K
Relative Volume:
0.39
時価総額：
$1.45B
収益：
$117.67M
当期純損益:
$-1.88B
株価収益率:
-0.6655
EPS:
-60.5369
ネットキャッシュフロー:
$-621.36M
1週間 パフォーマンス:
+14.49%
1か月 パフォーマンス:
-12.74%
6か月 パフォーマンス:
+40.82%
1年 パフォーマンス:
+154.28%
1日の値動き範囲:
$39.01
$40.62
1週間の範囲:
$33.73
$41.22
52週間の値動き範囲:
$12.33
$63.99
Grail Inc Stock (GRAL) Company Profile
GRAL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
40.29 | 1.43B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
|
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
|
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-10-17 | 開始されました | Guggenheim | Neutral |
Grail Inc (GRAL) 最新ニュース
What institutional investors are buying GRAIL LLC stockRapid portfolio appreciation - jammulinksnews.com
What markets is GRAIL LLC expanding into Is Cadiz Inc. stock a good long term investment optionDiscover high-impact stocks for your portfolio - jammulinksnews.com
How strong is GRAIL LLC company’s balance sheetBuild a portfolio with strong long-term growth - jammulinksnews.com
Is GRAIL LLC a good long term investmentExplosive earning power - PrintWeekIndia
What analysts say about GRAIL LLC stockFree Stock Market Real-Time Monitoring - PrintWeekIndia
"The Grail Collection" Could Be a Game-Changer for MDCE (OTC:MDCE)Jordan, Curry, and NBA Royalty Up for Bid - ACCESS Newswire
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
GRAIL LLC Stock Analysis and ForecastBreakout portfolio performance - Autocar Professional
What drives GRAIL LLC stock priceHigh-yield trading alerts - Autocar Professional
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
(GRAL) Technical Data - news.stocktradersdaily.com
Grail posts latest trial data for Galleri cancer detection test - MSN
Grail’s CFO Freidin sells $311k in common stock By Investing.com - Investing.com India
Grail’s CFO Freidin sells $311k in common stock - Investing.com Australia
Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance - MSN
GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission - MSN
12 Best Young Stocks To Buy and Hold For 5 Years - Insider Monkey
Illumina: A Compelling Buy Despite GRAIL Divestiture and Macroeconomic Challenges - AInvest
Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds - Seeking Alpha
Grail (GRAL): A High-Reward, High-Risk Play on Cancer Detection's Future - AInvest
15 Successful Spin-Off Companies and Their 2025 Returns - Insider Monkey
GRAIL Insiders Selling US$10m In Stock Relieved As Market Cap Slides To US$1.7b - simplywall.st
GRAIL's Insider Sales: Red Flag or Strategic Move? Assessing Executive Confidence Amid Strong Financials - AInvest
(GRAL) Trading Report - news.stocktradersdaily.com
GRAIL, Inc.(NasdaqGS: GRAL) added to Russell 2500 Value Index - MarketScreener
GRAIL, Inc.(NasdaqGS: GRAL) dropped from Russell Midcap Index - MarketScreener
Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone - CancerNetwork
Morgan Stanley raises Grail stock price target to $38 on cancer test potential - Investing.com
Grail plans FDA filing for cancer blood test after new trial - pharmaphorum
Grail reports positive outcomes from registrational study of Galleri test - Yahoo Home
PATHFINDER 2 Trial Releases Positive Topline Data for Multicancer Early Detection Test - OncLive
Grail plans to submit updated Galleri blood test for FDA approval next year - Fierce Biotech
Grail stock gains on new data for Galleri cancer test (GRAL) - Seeking Alpha
GRAIL reports positive results from cancer detection test study By Investing.com - Investing.com Nigeria
GRAIL reports positive results from cancer detection test study - Investing.com Australia
GRAIL Announces Positive Top-Line Results From The Galleri PATHFINDER 2 Registrational Study - MarketScreener
Grail reports results from PATHFINDER 2 study - TipRanks
Revolutionary Cancer Screening Test Achieves Major Clinical Success: GRAIL's Galleri Outperforms Previous Study - Stock Titan
GRAL Stock Surges: What Drives the Excitement? - timothysykes.com
GRAIL: Too Much A Leap Of Faith (NASDAQ:GRAL) - Seeking Alpha
California State Teachers Retirement System Takes $464,000 Position in Grail, Inc. (NASDAQ:GRAL) - Defense World
67,288 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Grail Inc (GRAL) 財務データ
収益
当期純利益
現金流量
EPS
1.50%
1.95%
大文字化:
|
ボリューム (24 時間):